Valeant Pharmaceuticals is launching a new $2 billion securities repurchase program, just days after losing to its bid to buy Botox maker Allergan to Actavis.
from WSJ.com: US Business http://ift.tt/1x5kncD
via IFTTT
from WSJ.com: US Business http://ift.tt/1x5kncD
via IFTTT
No comments:
Post a Comment